Cara Therapeutics Inc (NAS:CARA)
$ 0.378 -0.0719 (-15.98%) Market Cap: 20.73 Mil Enterprise Value: -13.94 Mil PE Ratio: 0 PB Ratio: 37.80 GF Score: 35/100

Cara Therapeutics, Inc. - KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus Call Transcript

May 29, 2019 / 12:30PM GMT
Release Date Price: $21.57 (+19.97%)
Operator

Good day, and welcome to the Cara Therapeutics KALM-1 Top Line Data Conference Call. (Operator Instructions) Please be advised that this call is being recorded at Cara's request. I will now like to turn the conference over to Cara team. Please proceed.

Michael Schaffzin
Stern Investor Relations, Inc. - Director

Good morning. This is Michael Schaffzin with Stern Investor Relations, and welcome to Cara Therapeutics KALM-1 Top Line Data Conference Call. The news release became available at 7:00 a.m. today and can be found at our -- on our website at www.caratherapeutics.com. You may also listen to a live webcast and replay of today's call in the Investors section of the website. A slide deck to accompany this call is also available for download on the Events & Presentations section at the Cara website.

Before we begin, let me remind you that statements made on today's call regarding matters that are not historical facts are forward-looking statements within the meaning of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot